Loading...
•
Dec 31, 2023
Intra-Cellular Q4 2023 Earnings Report
Intra-Cellular Therapies reported strong Q4 2023 results driven by increased CAPLYTA sales and provided full year 2024 financial outlook.
Key Takeaways
Intra-Cellular Therapies reported a net loss of $28.6 million for Q4 2023, with CAPLYTA net product sales reaching $131.5 million, a 50% increase over Q4 2022. The company's full-year revenue for 2023 was $464.4 million, including $462.2 million in CAPLYTA net product sales, representing an 86% year-over-year growth. The company anticipates CAPLYTA 2024 net product sales of $645 to $675 million.
CAPLYTA net product sales for Q4 2023 reached $131.5 million, a 50% increase compared to Q4 2022.
Full year 2023 CAPLYTA net product sales were $462.2 million, representing an 86% increase year-over-year.
Net loss for Q4 2023 was $28.6 million, compared to a net loss of $44.0 million for the same period in 2022.
CAPLYTA 2024 net product sales are expected to be $645 to $675 million.
Intra-Cellular
Intra-Cellular
Forward Guidance
Intra-Cellular Therapies provided full year 2024 financial outlook.
Positive Outlook
- CAPLYTA 2024 net product sales are expected to be $645 to $675 million.
- SG&A expenses for the full year 2024 are expected to be $450 to $480 million.
- R&D expenses for the full year 2024 are expected to be $215 to $240 million.
- The company is focused on continuing CAPLYTA’s momentum.
- The company is advancing its pipeline.